<DOC>
	<DOCNO>NCT03071224</DOCNO>
	<brief_summary>The overall goal protocol evaluate [ 18F ] MK-6240 ( also know [ 18F ] MNI-946 ) tau target radiopharmaceutical .</brief_summary>
	<brief_title>Phase 1 Test-retest Evaluation 18FMK-6240 PET Imaging Marker Neurofibrillary Tangles Brain</brief_title>
	<detailed_description>The overall goal protocol evaluate [ 18F ] MK-6240 ( also know [ 18F ] MNI-946 ) tau target radiopharmaceutical . - To measure dynamic uptake washout [ 18F ] MK-6240 brain use positron emission tomography ( PET ) patient Alzheimer 's disease healthy volunteer . - To measure blood metabolite [ 18F ] MK-6240 perform kinetic modeling ass ability measure tau protein brain use tracer plasma concentration reference region indirect input . - To obtain test/retest reliability tracer bind parameter patient Alzheimer 's disease healthy volunteer . - To acquire safety data follow injection [ 18F ] MK-6240 .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Female subject must document medical record physician 's note either surgically sterile ( mean hysterectomy , bilateral oophorectomy , tubal ligation ) postmenopausal least 1 year , childbearing potential , must commit use two method contraception , one barrier method duration study . Male subject partner childbearing potential must commit use two method contraception , one barrier method male subject study duration . Male subject must donate sperm study duration . Willing able cooperate study procedure Inclusion Criteria healthy volunteer subject : Males female age ≥ 50 year . Healthy clinically relevant find physical examination screen upon report [ 18F ] MK6240 image visit . No cognitive impairment neuropsychological battery judge investigator Have screen [ 18F ] florbetapir PET image demonstrate significant amyloid binding base qualitative ( visual read ) . No family history Alzheimer 's disease neurological disease associate dementia Have CDR score=0 Inclusion Criteria subject diagnosis probable Alzheimer 's disease ( AD ) : Males female age 50 80 year . Have probable Alzheimer 's disease , base NINCDS/ADRDA DSMIV criterion , mild severity amnestic presentation . Have CDR score ≥ 0.5 screen Have MMSE score 1026 ( inclusive ) . Have screen prior ( last 12 month ) [ 18F ] florbetapir PET image demonstrate amyloid binding base qualitative ( visual read ) . A brain MRI support diagnosis AD , evidence significant neurologic pathology . Medications take symptomatic treatment AD must maintain stable dosage regimen least 30 day screen visit . Signed date write informed consent obtain subject subject 's legally authorize representative caregiver ( applicable ) . The subject appropriate caregiver capable accompany subject visit , necessary . Current prior history alcohol drug abuse . Laboratory test clinically significant abnormality and/or clinically significant unstable medical illness . Subject receive investigational drug device within 30 day screen Prior participation research protocols clinical care last year radiation exposure exceed effective dose 50 mSv , would acceptable annual limit establish US Federal Guidelines . Pregnancy , lactate breastfeeding . Evidence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , neoplastic , endocrine , alternative neurological , immunodeficiency , pulmonary , disorder disease . Unsuitable vein repeat venipuncture . MRI exclusion criterion include : Findings cerebrovascular disease ( two lacunar infarct , territorial infarct &gt; 1cm3 , deep white matter abnormality correspond overall Fazekas scale 3 least one confluent hyperintense lesion FLAIR sequence ≥20 mm dimension ) , infectious disease , spaceoccupying lesion , normal pressure hydrocephalus abnormality associate CNS disease . Implants implanted cardiac pacemaker defibrillator , insulin pump , cochlear implant , metallic ocular foreign body , implanted neural stimulators , CNS aneurysm clip medical implant certify MRI , history claustrophobia MRI . Exclusion criterion subject AD : • Has receive treatment target amyloidβ tau within last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AD</keyword>
	<keyword>HV</keyword>
</DOC>